There has never been a more exciting and promising time in pharmacological research related to obesity drugs. It is now broadly accepted that obesity is not just a lack of willpower but a complex chronic disease with increased morbidity and mortality that can be managed with the right treatment.

Over the past decade or so, gut hormone-based drug development targeting obesity and type 2 diabetes indications and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) as dual or triple agonists or other complementary mode of action have increased rapidly.

Semaglutide and, most recently, tirzepatide have demonstrated that a two-digit weight loss at one year is achievable and the Phase II data with retatrutide suggest that 100 percent of patients can now achieve the 5 percent weight loss that was targeted in the past. The next stage in obesity research needs to bring affordable and accessible drugs that can lead to selective fat loss, preservation of lean body mass and long-term weight maintenance. As with many other chronic diseases, combination therapies with complementary modes of action will be required to successfully treat patients with obesity.

Speakers

Dr. Eric Ravussin, PhD, Boyd Professor, Douglas L. Gordon Chair in Diabetes and Metabolism, Pennington Biomedical Research Center-LSU System, Baton Rouge, Louisiana

Dr. Eric Ravussin is a Boyd Professor at Louisiana State University. He received his PhD in human physiology at the University of Lausanne, Switzerland. Dr. Ravussin is an internationally recognized Translational Investigator in obesity and diabetes research. His research now focuses on the molecular basis of obesity and its co-morbidities.

His studies are aimed at understanding the molecular mechanisms that determine the inter-individual variability in energy expenditure, fat oxidation and energy balance in response to caloric restriction, increased or decreased physical activity, overfeeding or physiological conditions such as puberty, pregnancy or menopause as well as pharmacological treatment.

Dr. Claudia Filozof, Vice President and Therapeutic Area Head in Obesity, MASH and Liver Indications, Fortrea

Dr. Claudia Filozof is Vice President and Therapeutic Area Head in Obesity, MASH and Hepatology indications. She is board certified in Nutrition and Metabolism. Her expertise is broad and ranges from clinical trials and drug development to Global medical affairs, across multiple therapy areas, with main focus in Metabolics, including Obesity, Diabetes, dyslipidemias, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASD) and multiple hepatology indications and rare diseases.

Dr. Filozof lead development programs in T2DM, obesity, severe high triglycerides and metabolic dysfunction associated steatotic liver disease (MASLD). Her interest in obesity and related metabolic conditions triggered her interest in MASLD/ MASH 13 years ago; during all these last years, she has been very active with the scientific community in this indication and published 6 review articles in drug development in MASLD.

Dr. Peter Alfinito, PhD, Executive Director, Operational Strategy & Planning, Fortrea

Dr. Peter Alfinito, PhD, is an Executive Director, Operational Strategy & Planning of CVMER (cardiovascular, metabolic, endocrine and renal) at Fortrea. Dr. Alfinito has more than 24 years of experience in academic research, large pharma drug discovery and clinical development, including nine years of specific cardiometabolic focus in the CRO industry.

Dr. Alfinito supports global clinical operational strategies and shares study planning expertise across Phases Ib-IV trials. He is specialized in the design and implementation of strategies to mitigate risk in late-phase studies, IIb-III, and is internationally recognized with more than 50 peer-reviewed publications. Dr. Alfinito has PhD in Biomedical Sciences from Rutgers University and a BA in Chemistry from Swarthmore College.

Message Presenter

Who Should Attend?

This webinar is designed for drug developers, healthcare professionals, patient advocacy groups and anyone interested in the advancement of obesity drug development.

What You Will Learn

Attendees will learn about:

Understanding obesity’s health burden and the evolution of drug development in obesity
Methodologies used to evaluate body composition in the context of obesity research
Potential additional targets beyond energy intake to enhance weight loss quality and maintenance
Current challenges in obesity clinical trials and strategies to mitigate these challenges for future research efforts

Xtalks Partner

Fortrea

Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account

New Era of Obesity Drug Development

Share this: